Patrys expands anti-cancer pipeline
18 June, 2010 by Tim DeanPatrys has expanded its pipeline of antibody-based treatments for cancer with two new additions, bringing its portfolio to 13 antibodies under development.
Local scientists take toxic sting out of fire-fighting-foam
18 June, 2010 by David BinningAustralian scientists have developed a technology for isolating the toxic chemicals escaping into the environment for the last 50 years from fire-fighting-foams.
SA scientist pioneers new system for organic waste
17 June, 2010 by David BinningA biotechnologist from the South Australian Research and Development Institute ( SARDI ) has demonstrated a unique ‘waste-food-chain’ with major implications for industries that product organic waste.
New study reveals role of gut hormone in insulin and blood sugar levels
17 June, 2010 by Staff WritersAn Australian and a British researcher have published the results of a breakthrough study expected to transform traditional thinking about the digestive process and possibly lead to new treatments for and other diseases.
Healthscope to provide OvPlex ovarian cancer test in Australia
15 June, 2010 by Staff WritersMelbourne biotech HealthLinx announced today that it will resume distribution its OvPlex ovarian cancer biomarker test through Healthscope’s national network of collection centres after the healthcare provider’s acquisition of ARL Pathology last year.
Market report: Local shares rise on U.S optimism about China and Europe
11 June, 2010 by David BinningThe Australian share market rose today following a strong lead from U.S markets overnight after China reported robust export data and European markets reversed some of their recent losses.
Avita’s ReCell spray-on-skin nearing U.S approval
10 June, 2010 by David BinningAvita Medical has announced exceptional results following the first FDA-approved treatment of a U.S burns patient with the company’s ReCell spray-on-skin treatment.
British biotech boasts antibiotic breakthrough
09 June, 2010 by David BinningA British biotech company is preparing for phase II trials of a new antibiotic being viewed as a major leap forward in the fight against drug -resistant strains of bacteria.
Government announces $440,000 to bolster overseas collaborations
08 June, 2010 by Staff WritersThe federal government has announced new funding of $440,000 to support 69 research collaborations between Australian and overseas groups, as part of the International Science Linkages – Science Academies Program.
Market Report: Aussie biotechs keep even keel amid cautious week
04 June, 2010 by David BinningDeclines in banks and miners pulled the S&P/ASX200 Index down today erasing Thursday’s gains and leaving the exchange pretty much where it started the week.
Prima BioMed gets European product designation
03 June, 2010 by Staff WritersPrima BioMed announced today that its CVac ovarian cancer therapy vaccine has been granted Orphan Medicinal Product Designation by the European Medicines Agency (EMA).
Burnett immunology centre gets nod from NATA
03 June, 2010 by Staff WritersThe Burnett Institute’s ImmunoMonitoring Facility (IMF) has become first such facility in Victoria, and only the fifth in Australia, to be accredited by the National Association of Testing Authorities of Australia.
Cochlear wins major design award
03 June, 2010 by Staff WritersCochlear has taken out this year’s coveted ‘red dot award:design’ for its Nucleus 5 System, a solution for people with severe to profound hearing loss.
New Aussie biofuels project
01 June, 2010 by David BinningAusBiotech will oversee a new federal government funded research project aiming to advance the understanding of second generation biofuels.
IP is key for medical tech companies
01 June, 2010 by Staff WritersA study looking at the $300 billion medical technology market has highlighted the need for Australian companies to be more mindful of protecting and promoting their IP if they want to share in the spoils.